VirTus Respiratory Research has played a key role in the development of Apollo Therapeutics’ APL-10456, supporting the programme through more than five years of preclinical research. Through over 20 studies, VirTus helped evaluate vaccine candidates, establish proof...
Virtus Respiratory Research Ltd is pleased to share that our collaboration with AltesaBiosciences, Inc. has contributed to the successful close of a $75 million oversubscribedSeries B financing.The financing follows positive results from a Phase 2a human rhinovirus...
Thank you for your interest in our clinical trial. This survey should take 2-3 minutes to complete and will be reviewed by the medical team to see whether you would be suitable for our trial. Please note: we will store this confidential medical information securely...
